Cannabidiol has been well-known to have the ability to relieve several common ailments. Popularly referred to as CBD, it’s part of the one hundred chemical compounds found in the marijuana or cannabis plant. THC or Tetrahydrocannabinol is the main psychoactive compound contained in cannabis and is what gives you that “high” sensation weed is popular for. But, CBD, unlike THC, isn’t psychoactive in nature. This is why this component is such an appealing alternative for those looking to relieve chronic pains and other ailments naturally.
Sativa Investments (NEX:SATI) is the UK’s first medicinal cannabis investment vehicle. After investing in two North American businesses, it is now progressing a UK seed to consumer investment strategy with 100% ownership of businesses involved in the production, testing and compliance, research & development including pharmacology, commercialisation and sales & marketing of medicinal cannabis and cannabidiol products. Two UK businesses, George Botanicals and PhytoVista Laboratories, are already fully operational.